CNS Involvement in Primary Mediastinal Large B-Cell Lymphoma

Bishop, Philippe C.; Wilson, Wyndham H.; Pearson, D; Janik, John E.; Jaffe, Elaine S.; Elwood, Patrick C.

doi:10.1200/jco.1999.17.8.2479

Cited by 109 publications

(88 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…73 At presentation, CNS disease is uncommon; 74 however, at the time of first relapse, the incidence has been reported to be as high as 23%. 75 In this analysis, parenchymal brain lesions predominated, but free lymphoma cells were not detected on cerebro-spinal fluid examination despite the presence of leptomeningeal involvement established by imaging. Bishop et al recommend CSF examination and careful neuroimaging in the presence of multiple extranodal sites or one nodal site when the LDH is elevated.…”

Section: Do Patients With Pmbl Require Central Nervous System Prophylmentioning

confidence: 56%

“…Bishop et al recommend CSF examination and careful neuroimaging in the presence of multiple extranodal sites or one nodal site when the LDH is elevated. 75 It seems appropriate that these at-risk patients are identified and should receive intrathecal prophylaxis, although the evidence base is lacking.…”

Section: Do Patients With Pmbl Require Central Nervous System Prophylmentioning

confidence: 99%

See 1 more Smart Citation

Primary mediastinal B‐cell lymphoma

Boleti

Johnson

2007

Hematological Oncology

View full text Add to dashboard Cite

Primary mediastinal B-cell lymphoma is a discrete clinicopathologic entity. Molecular analysis reveals it to be distinct from other types of large B-cell lymphoma, and retrospective analysis suggests that it may respond better to multi-agent chemotherapy regimens than to the more commonly used CHOP. The addition of rituximab may mitigate such differences, and may also diminish the role of consolidation radiotherapy, which is often used to treat residual mediastinal masses. For the future the role of FDG-PET scanning requires prospective examination, and it is hoped that this may allow the de-escalation of treatment if it can be shown to yield reliable prognostic information. The relative rarity of this type of lymphoma necessitates international collaboration in clinical trials, with a prospective clinicopathologic study, IELSG 26, already underway.

show abstract

Section: Do Patients With Pmbl Require Central Nervous System Prophylmentioning

confidence: 56%

Section: Do Patients With Pmbl Require Central Nervous System Prophylmentioning

confidence: 99%

Primary mediastinal B‐cell lymphoma

Boleti

Johnson

2007

Hematological Oncology

View full text Add to dashboard Cite

show abstract

“…The incidence of leptomeningeal disease at diagnosis ranges from 3.7% to 25%, and it is related to several factors, such as the different histological subtypes, the involvement of particular sites of disease (ie, testis, bone marrow, Waldeyer ring, or retroperitoneal masses), and an increased serum lactate dehydrogenase (LDH) level. [1][2][3][4][5][6][7][8][9][10][11] Moreover, the overall incidence of CNS recurrence with or without intrathecal prophylaxis is around 5%. 3,[12][13][14][15] Since the beginning of the acquired immune deficiency syndrome (AIDS) epidemic, a close association between human immunodeficiency virus (HIV) infection and high-grade NHL has been reported.…”

mentioning

confidence: 99%

Phase 2 study of intrathecal, long‐acting liposomal cytarabine in the prophylaxis of lymphomatous meningitis in human immunodeficiency virus‐related non‐Hodgkin lymphoma

Spina

Chimienti

Martellotta

et al. 2010

Cancer

View full text Add to dashboard Cite

BACKGROUND:Patients with aggressive non-Hodgkin lymphoma (NHL) develop central nervous system (CNS) progression or recurrence during the course of their disease. Patients with human immunodeficiency virus (HIV)-NHL often develop CNS progression despite the use of prophylaxis. Liposomal cytarabine (DepoCyte) has shown activity in lymphomatous meningitis, but there are limited data for prophylaxis. METHODS: Between May 2006 and December 2008, a phase 2 study of intrathecal liposomal cytarabine was performed at the dose of 50 mg in 30 patients with HIV-NHL, with the aim of evaluating feasibility and activity for prophylaxis. RESULTS: Liposomal cytarabine was well tolerated, with headache grade I to III being the most frequent side effect in 40% of patients. With a median followup of 10.5 months, only 1 (3%) patient developed a combined systemic and meningeal recurrence. The use of liposomal cytarabine allowed significant reduction of the number of lumbar injections in comparison to the standard schedules (around 50%), improving the quality of life of patients and reducing the professional exposure risk. CONCLUSIONS: In this first study on prophylaxis of lymphomatous meningitis in HIV-NHL, liposomal cytarabine seems safe and active; it reduces by approximately 50% the number of lumbar punctures, and exposure risk for health staff as well.

show abstract

“…1,5,14,20 -22 Clinically, mediastinal (thymic) B-cell lymphoma is characterized by aggressive local growth frequently involving the lung and, eventually it , "metastasizes" to other organs such as liver and kidney, and brain. 23 Although locoregional (e.g., supraclavicular) lymph node involvement may occur, generalized lymphomatous spread or bone marrow involvement or leukemia has not been reported so far. We now present MedB-1, a novel B-cell line, and, by IgH gene rearrangement and immunology provide evidence for its clonal derivation from a typical primary mediastinal B-cell lymphoma.…”

mentioning

confidence: 99%

MedB-1, a human tumor cell line derived from a primary mediastinal large B-cell lymphoma

et al. 2001

View full text Add to dashboard Cite

Primary mediastinal B-cell lymphoma is a locally highly aggressive but poorly disseminating tumor composed of medium sized or large cells most probably of thymic medullary origin. It has a mature B-cell phenotype, typically lacks immunoglobulin expression and has variable defects in expression of HLA-molecules. We present here a cell line, MedB-1, derived from such a tumor. As is frequently found in mediastinal B-cell lymphomas in situ, MedB-1 is CD10 ؊ , CD19 ؉ ,

show abstract

CNS Involvement in Primary Mediastinal Large B-Cell Lymphoma

Cited by 109 publications

References 38 publications

Primary mediastinal B‐cell lymphoma

Primary mediastinal B‐cell lymphoma

Phase 2 study of intrathecal, long‐acting liposomal cytarabine in the prophylaxis of lymphomatous meningitis in human immunodeficiency virus‐related non‐Hodgkin lymphoma

MedB-1, a human tumor cell line derived from a primary mediastinal large B-cell lymphoma

Contact Info

Product

Resources

About